Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The incidence of port-site metastases might be reduced.
Reymond MA, Wittekind C, Jung A, Hohenberger W, Kirchner T, Köckerling F. Reymond MA, et al. Among authors: jung a. Surg Endosc. 1997 Sep;11(9):902-6. doi: 10.1007/s004649900483. Surg Endosc. 1997. PMID: 9294269
[Regional cooperation in molecular biology topics].
Reymond MA, Köckerling F, Jung A, Kirchner T, Fuchs KH, Jauch H, Hohenberger W. Reymond MA, et al. Among authors: jung a. Langenbecks Arch Chir Suppl Kongressbd. 1997;114:370-1. Langenbecks Arch Chir Suppl Kongressbd. 1997. PMID: 9574157 German.
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Modest DP, et al. Among authors: jung a. Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358379 Free PMC article.
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group. Michl M, et al. Among authors: jung a. Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234640 Free article. Clinical Trial.
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.
Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A. Stintzing S, et al. Among authors: jung a. Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018. Front Oncol. 2018. PMID: 30467535 Free PMC article.
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Vangala D, et al. Among authors: jung a. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. Genome Med. 2021. PMID: 34271981 Free PMC article.
1,840 results